Advice

in the absence of a submission from the holder of the marketing authorisation:

letermovir (Prevymis®) is not recommended for use within NHSScotland.

Indication under review: for prophylaxis of cytomegalovirus (CMV) disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-].

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

Download detailed advice215KB (PDF)

Download

Medicine details

Medicine name:
letermovir (Prevymis)
SMC ID:
SMC2853
Indication:

For prophylaxis of cytomegalovirus (CMV) disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-].

Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Infections
Submission type
Non submission
Status
Not recommended
Date advice published
11 August 2025